How should vonoprazan be used in H. pylori eradication therapy, including recommended dosing and alternatives for macrolide‑resistant strains?

Vonoprazan for H. pylori Eradication

Vonoprazan should be used at 20 mg twice daily with antibiotics for 14 days as first-line therapy for H. pylori eradication, and is particularly superior for clarithromycin-resistant strains. 1

Recommended Dosing Regimens

Standard Triple Therapy (First-Line)

• Vonoprazan 20 mg twice daily + amoxicillin 1000 mg twice daily + clarithromycin 500 mg twice daily for 14 days 2
• This is the FDA-approved regimen in the United States
• Achieves eradication rates of 88-93% in intention-to-treat analysis 1, 3

Dual Therapy Alternative

• Vonoprazan 20 mg twice daily + amoxicillin 750 mg three or four times daily for 14 days
• Achieves 85-92% eradication rates 1
• Critical advantage: Reduces antibiotic burden by eliminating clarithromycin 4
• The 14-day duration is superior to 10-day therapy (88% vs 83.3% eradication) 5

Quadruple Therapy

• Vonoprazan 20 mg twice daily + amoxicillin + bismuth + furazolidone for 10-14 days
• Achieves 96-97% eradication rates in per-protocol analysis 6
• Can be considered when higher eradication certainty is needed

Superiority in Clarithromycin-Resistant Strains

This is where vonoprazan truly excels. For clarithromycin-resistant H. pylori:

• Vonoprazan-based regimens achieve 66-82% eradication vs only 32-40% with PPI-based therapy 1, 7
• Vonoprazan dual therapy (without clarithromycin) achieves 92% eradication in clarithromycin-resistant strains 1
• This represents a 2-fold improvement over PPI-based triple therapy containing clarithromycin

The mechanism: Vonoprazan's superior acid suppression (maintaining pH >6 for 75-97% of the day) enhances amoxicillin efficacy, which is pH-dependent 5

Dose Adjustments for Special Populations

Renal Impairment

• eGFR ≥30 mL/min: 20 mg twice daily (standard dose)
• eGFR <30 mL/min: Not recommended for H. pylori treatment 2

Hepatic Impairment

• Child-Pugh Class A: 20 mg twice daily (standard dose)
• Child-Pugh Class B or C: Not recommended for H. pylori treatment 2

Clinical Decision Algorithm

Use vonoprazan-based therapy when:

1. First-line therapy in any patient - Superior to PPI-based regimens (92% vs 80% eradication) 1

2. Known or suspected clarithromycin resistance:

   • Prior macrolide exposure for any indication 8
   • Geographic areas with >15% clarithromycin resistance
   • Choose dual therapy (vonoprazan + amoxicillin) to avoid futile clarithromycin use 1, 7

3. PPI treatment failures - Vonoprazan overcomes CYP2C19 polymorphism issues that affect PPI efficacy 8

4. Penicillin allergy considerations:

   • If no anaphylaxis history, pursue penicillin allergy testing to enable amoxicillin use 8
   • Amoxicillin resistance remains rare and is critical for vonoprazan-based regimens 8

Key Advantages Over PPI-Based Therapy

• Rapid, potent acid suppression: pH >6 achieved within 4-5 hours and maintained at 7-9 5
• No CYP2C19 polymorphism effect: Consistent efficacy regardless of metabolizer status 2
• Shorter treatment duration possible: 7-day dual therapy achieves 85-89% eradication 1
• Lower adverse event rates: 19-34% vs 43% with bismuth quadruple therapy 4, 3

Critical Pitfalls to Avoid

1. Do not use 10-day vonoprazan dual therapy - Noninferiority to 14-day therapy was not established (83% vs 88% eradication) 5

2. Do not repeat clarithromycin if prior macrolide exposure exists - Resistance rates approach 100% after macrolide use 8

3. Ensure adequate amoxicillin dosing: Minimum 2g daily divided three to four times daily to avoid low trough levels 8

4. Do not assume vonoprazan overcomes all resistance - For clarithromycin-sensitive strains, triple therapy with clarithromycin remains slightly superior to dual therapy (93% vs 87%) 1

Cost Considerations

While vonoprazan costs more than PPIs, the superior eradication rates (particularly avoiding treatment failures) and reduced antibiotic burden with dual therapy provide favorable cost-effectiveness ratios 1, 6. The short 14-day duration for H. pylori eradication reduces cost concerns compared to long-term GERD therapy 1.

The 2022 Maastricht VI/Florence Consensus achieved 100% expert agreement that vonoprazan-based regimens are superior to conventional PPI-based triple therapies, especially for antimicrobial-resistant infections 1.